Game-changing new treatments such as emicizumab feature heavily in the new and expanded World Haemophilia Federation (WHF) guidelines for the management of haemophilia. For example, the 3rd edition of the WHF guidelines recommends prophylaxis with emicizumab to prevent haemarthrosis, spontaneous, and breakthrough bleeding in patients with severe phenotype haemophilia A without inhibitors. However the recommendations ...
New haemophilia guidelines emphasise outcomes with newer agents
By Mardi Chapman
22 Sep 2020